From HLA peptides to actionable insight
Antogen provides immunopeptidomics services to identify and quantify peptide–HLA ligands directly from biological samples — supporting discovery programs and translational studies in oncology, immunotherapy development, and autoimmune disease research.
Why Antogen
Deep HLA expertise built for both discovery and translational programs
Qualitative and quantitative, decision-ready outputs to priority actionable targets
A specialty CRO helping you elucidate TCR ligands including TAA's, neoantigens, self-reactive peptides
Your Partner on the Clinical Journey
DISCOVERY WORKSTREAMS
Disease hypothesis & unmet need
Define biology and therapeutic rationale
Target discovery
Identify disease-associated peptides/targets
Target validation
Confirm relevance, selectivity and mechanism
Candidate selection
Prioritize programs with translational potential
Discovery platform
Reveal novel and previously unknown disease-associated peptides
Support target discovery and pipeline expansion abc
Enable earlier go/no-go decisions
CLINICAL VALIDATION WORKSTREAMS
Biomarker & patient stratification strategy
Find likely responders before enrollment
Early clinical trials (Phase 1/2)
Generate signal, reduce heterogeneity
Pivotal trials & registration
Strengthen statistical outcome and evidence package
Approved therapeutic
Improved path to approval
Clinical trial support
Screen patients in advance of enrollment
Identify patients most likely to respond
De-risk trials by improving cohort selection and statistical signal
Screen Targets against a Healthy Tissues Database
Antogen has prepared a comprehensive immunopeptidome library to reduce or eliminate off-target risks and accelerate candidate selection
Supported Sample Types
Tissue
Biopsies
Cell Lines
Peripheral Blood
Who We Support
Pharmaceutical pre-clinical and clinical teams
Biotechnology companies
